Imagion Biosystems 2017 MagSense Cancer Diagnostic Technology

Imagion Biosystems presents MagSense™, a clinical diagnostic technology platform for early cancer detection targeting breast, prostate, and ovarian cancers. The company leverages proprietary technology covered by eight patents through 2029 and has established pre-clinical partnerships with leading medical research institutes. The platform operates on a "printer and ink" model combining diagnostic instruments with consumables, addressing a $100 billion global market opportunity.